Wednesday, October 14, 2026

Dell, NVIDIA, Oracle Fight to Own Enterprise AI Stack as Domain Expertise Displaces Model Access

Five tech incumbents — Dell, NVIDIA, Snowflake, Oracle, and Google — are converging on enterprise AI infrastructure in 2026, betting embedded institutional knowledge outcompetes raw model access. Customers Bancorp has deployed 500+ custom AI agents; Amgen restructured leadership entirely around AI. The startup-versus-incumbent debate is resolving in favor of whoever already sits inside enterprise operations.

LM Salvado
LM Salvado

April 27, 2026

Source Trace Score9 source documents9 with a live linkVerifiability: Strong
Dell, NVIDIA, Oracle Fight to Own Enterprise AI Stack as Domain Expertise Displaces Model Access
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Five tech giants — Dell, NVIDIA, Snowflake, Oracle, and Google — are racing to own the enterprise AI data and compute stack in 2026, converging on infrastructure as the decisive battleground.1

The strategic logic is direct. OpenAI and Anthropic sell stateless intelligence: capable, increasingly interchangeable, and disconnected from enterprise operations. The durable competitive moat belongs to whoever embeds accumulated institutional knowledge into AI systems that compound over time.1

Ensemble, an enterprise AI platform, frames the distinction precisely: "Model providers like OpenAI and Anthropic sell intelligence as a service... That intelligence is general-purpose, largely stateless, and only loosely connected to the day-to-day operations where decisions are made."1

Real-world deployments are validating the thesis. Customers Bancorp has deployed more than 500 custom AI agents. Amgen restructured its entire leadership around AI, creating a new CTO role and an EVP of R&D, AI, and Data.2

Dell's partnership with NVIDIA targets this layer directly — combining data orchestration and storage innovation to give enterprises the infrastructure to build proprietary AI systems on top of shared model providers.3

A structural advantage reinforces the incumbent position. Large language models hallucinate on information beyond their training cutoff. Han Xiao, writing in MIT Technology Review, identifies the fix: "forcing the model to work from verified sources" — a capability enterprises with mature data infrastructure already hold.4

Public sector adoption illustrates what happens without that foundation. Government AI deployment is blocked not by model capability gaps but by data sovereignty requirements, infrastructure ownership questions, and reliability demands.4

The startup-versus-incumbent debate turns on whether enterprise AI is a model problem or a systems problem. Ensemble is direct: in high-volume, high-stakes domains, advantage accrues to whoever already manages integrations, permissions, evaluation, and change management inside enterprise operations.1

Ensemble's design philosophy follows: "The goal is to permanently embed the accumulated expertise of thousands of domain experts — their knowledge, decisions, and reasoning — into an AI platform that amplifies what every operator can accomplish."1

For investors, the read-through is straightforward. Infrastructure and data layer plays — NVIDIA, Oracle, Snowflake, Dell, Google — carry structurally deeper moats than application-layer startups competing on model access alone.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score9 source documents9 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· April 21, 2026
    Introducing Osirus AI, the Unified Platform for Building, Deploying, and Managing Enterprise AI Agents
  2. [2]News articleMIT Technology Review
    Making AI operational in constrained public sector environments
  3. [3]News articleYahoo Finance· April 21, 2026
    Snowflake Expands Snowflake Intelligence and Cortex Code to Power the Control Plane for the Agentic Enterprise
  4. [4]News articleMIT Technology Review
    Treating enterprise AI as an operating layer
  5. [5]News articleYahoo Finance· April 22, 2026
    AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
  6. [6]Press releaseGlobeNewswire· March 24, 2026
    Cloudera Membawa Era Awan di Mana Saja ke Persidangan Tahunan Global Data dan AI, EVOLVE26
  7. [7]News articleYahoo Finance· March 16, 2026
    Dell AI Data Platform with NVIDIA Supercharges Enterprise AI with Breakthrough Data Orchestration and Storage Innovations
  8. [8]News articleYahoo Finance· April 22, 2026
    Snowflake Makes AI Real for Businesses at Snowflake Summit 26, Featuring Anthropic’s Daniela Amodei and Other Industry Leaders
  9. [9]News articleYahoo Finance· April 19, 2026
    STT Q1 Deep Dive: Fee Revenue, Digital Innovation, and AI Transformation Propel Results

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com